Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.34 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 410.13K shares, a 2.40% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.93M shares, a 19.78% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 64.00K shares, a 50.69% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 360.00K shares, a 260.00% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.43M shares, a 19.38% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.02M shares, a 394.20% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 610.64K shares.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 2.73M shares, a 50.87% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 410.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 2.34M shares 10-Q · filed 2026-08-04 | 2.40M shares derived: sum of 3 quarters · filed 2026-08-04 | 2.76M shares derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | 1.93M shares 10-Q · filed 2026-05-05 | 1.99M shares derived: sum of 2 quarters · filed 2026-05-05 | 2.35M shares derived: sum of 3 quarters · filed 2026-05-05 | 2.75M shares derived: sum of 4 quarters · filed 2026-05-05 | |
| 2025-12-31 | 64.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 424.00K shares derived: sum of 2 quarters · filed 2026-03-09 | 824.50K shares derived: sum of 3 quarters · filed 2026-03-09 | 2.43M shares 10-K · filed 2026-03-09 | |
| 2025-09-30 | 360.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 760.50K shares derived: sum of 2 quarters · filed 2025-11-05 | 2.37M shares 10-Q · filed 2025-11-05 | 2.50M shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-06-30 | 400.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.01M shares 10-Q · filed 2025-08-07 | 2.14M shares derived: sum of 3 quarters · filed 2025-08-07 | 2.24M shares derived: sum of 4 quarters · filed 2025-08-07 | |
| 2025-03-31 | 1.61M shares 10-Q · filed 2025-05-12 | 1.74M shares derived: sum of 2 quarters · filed 2025-05-12 | 1.84M shares derived: sum of 3 quarters · filed 2025-05-12 | 3.23M shares derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | 129.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 229.80K shares derived: sum of 2 quarters · filed 2025-03-11 | 1.62M shares derived: sum of 3 quarters · filed 2025-03-11 | 3.02M shares 10-K · filed 2025-03-11 | |
| 2024-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.49M shares derived: sum of 2 quarters · filed 2024-11-07 | 2.89M shares 10-Q · filed 2024-11-07 | 3.06M shares derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | 1.39M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.79M shares 10-Q · filed 2024-08-08 | 2.96M shares derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2024-03-31 | 1.40M shares 10-Q · filed 2024-05-09 | 1.57M shares derived: sum of 2 quarters · filed 2024-05-09 | |||
| 2023-12-31 | 170.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 610.64K shares 10-K · filed 2024-03-21 | |||
| 2023-09-30 | 440.04K shares 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | 1.03M shares 8-K · filed 2023-12-21 | 4.51M shares 10-K · filed 2023-03-23 | |||
| 2021-12-31 | 248.60K shares 8-K · filed 2023-12-21 | 3.10M shares 10-K · filed 2022-03-08 | |||
| 2020-12-31 | 2.73M shares 10-K · filed 2021-03-03 | ||||
| 2019-12-31 | 1.81M shares 10-K · filed 2020-03-03 | ||||
| 2018-12-31 | 3.12M shares 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |